Welcome to our dedicated page for Renalytix plc American Depositary Shares news (Ticker: RNLX), a resource for investors and traders seeking the latest updates and insights on Renalytix plc American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Renalytix plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Renalytix plc American Depositary Shares's position in the market.
Renalytix Plc (NASDAQ: RNLX) appointed Joseph Hutson as Vice President of Quality and Regulatory to enhance its KidneyIntelX commercialization strategy. With over 23 years in life sciences and experience at Abbott and Becton Dickinson, Hutson will focus on ensuring compliance with regulatory standards, including FDA and IVDR. KidneyIntelX is currently under FDA review for De Novo marketing authorization as a Breakthrough Device. Renalytix aims to improve kidney disease diagnostics, addressing a significant public health issue affecting millions globally.
Renalytix (NASDAQ: RNLX) presents new study data indicating that KidneyIntelX effectively monitors kidney health in adults with type 2 diabetes. The international study involving 1,100 patients highlighted KidneyIntelX’s role in assessing therapeutic responses, particularly for those at high risk of kidney failure. This data will support collaborations for repeat testing and reimbursement, enhancing early risk stratification and treatment optimization in chronic kidney disease. The findings were shared at the American Diabetes Association event.
Renalytix AI plc (NASDAQ: RNLX) reported financial results for the quarter ended March 31, 2021, showing revenue of $0.6 million in services and $0.1 million in testing. The company announced partnerships with University of Utah and Atrium Health to improve kidney health. A significant 10-year contract with the U.S. General Services Administration was secured for KidneyIntelX testing at $950 per report. However, the net loss attributable to shareholders was $8.8 million, up from $0.7 million year-over-year, while cash reserves rose to $70.1 million.
Renalytix AI (NASDAQ: RNLX) announced a change of auditor to Ernst & Young LLP, effective May 12, 2021. The company will release its fiscal Q3 2021 financial results on June 15, 2021, prior to market opening, and will hold a conference call at 8:30 a.m. EDT to discuss the results. Notably, there were no disagreements with the previous auditor, Deloitte & Touche LLP, regarding accounting practices or auditing procedures. Renalytix AI focuses on artificial intelligence-enabled diagnostics for kidney disease management.
Renalytix AI (NASDAQ: RNLX) has announced key leadership hires to accelerate its commercialization strategy for the KidneyIntelX testing system, targeting early-stage diabetic kidney disease. The new team, experienced in sales, marketing, and healthcare partnerships, is poised to enhance adoption in the VA Medical Health System and expand into national markets. The company anticipates a broader roll-out in fiscal 2022, aligned with potential Medicare coverage. Kidney disease affects over 850 million globally, highlighting the urgency of Renalytix's solutions.
Renalytix AI plc (NASDAQ: RNLX) has released results from a utility study highlighting the significance of early-stage diabetic kidney disease (DKD) risk assessments. Conducted with 16 primary care physicians, the study found that 100% confirmed the necessity of accurate risk assessment to enhance patient management and adherence, which are crucial for preventing DKD progression. The KidneyIntelX platform demonstrated potential in predicting DKD progression, suggesting its adoption could improve outcomes and decrease healthcare costs.
Kantaro Biosciences, a joint venture involving RenalytixAI (RNLX) and the Mount Sinai Health System, has received Health Canada Authorization for its COVID-SeroKlir semi-quantitative antibody test kit. This kit can detect the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity. Importantly, it is available for immediate use in Canadian laboratories without proprietary equipment. The test has already been deployed over 127,000 times on diverse populations, offering significant potential for guiding public health policies as Canada reopens.
Renalytix AI plc (NASDAQ: RNLX) partners with Atrium Health and Wake Forest School of Medicine to enhance kidney disease management. The partnership will utilize the KidneyIntelX platform for early-stage diabetic kidney disease risk assessment, integrated into Atrium's EHR system across 37 hospitals, serving over 7 million people. This initiative aims to reduce kidney disease progression and improve patient outcomes through data-driven insights. A multi-center program over five years promotes comprehensive care to enhance healthcare delivery and costs.
Summary not available.
Renalytix AI has secured a 10-year contract from the U.S. Government to provide KidneyIntelX testing services across over 140 government departments and agencies. Effective April 15, 2021, this contract, valued at $950 per test, enhances access to early-stage kidney disease diagnostics. The contract aims to benefit veterans and active military personnel, offering crucial early detection of chronic kidney disease (CKD). Dr. James Post highlights its significance in managing CKD before nephrologist intervention. The contract supports Renalytix AI's market access strategy and broadens patient care delivery.